Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

George Rathmann

Amgen Inc.

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Acerta Pharma, an affiliate of AstraZeneca, develops and delivers targeted novel transformational medicines for patients with hematological malignancies.  Acerta Pharma uses innovative approaches to discover, develop, and deliver targeted medicines, focusing on innovative clinical strategies and resistance biology.

Acerta Pharma

ATXA Therapeutics is a clinical-stage pharmaceutical company committed to the advancement of innovative treatments for cardiopulmonary diseases. Self-described as focusing on developing novel antagonists of the Thromboxane Receptor (TP).

ATXA Therapeutics

Amgen Netherlands

Amgen Oncology

Amgen France

Amgen Deutschland

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

See our Community Guidelines: bit.ly/smcgl
See our Global Privacy Statement Directory: www.amgen.com/dp

Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

SomaLogic

Unilife Corporation

Science 37

BeiGene

immatics biotechnologies

Jasper Therapeutics

Oxford Nanopore Technologies

Amgen

See what’s happening at our second-largest research and development facility: Amgen San Francisco.

Thanks to Jason DeVoss for the exclusive tour. 

At Amgen, we join forces with the healthcare community to unlock innovative therapies, giving cancer patients the chance to look ahead with renewed optimism. Together, we fight for a brighter future. 
#AmgenHellas #WorldCancerDay

Amgen's P. Ryan Potts, Ph.D. is the featured scientist on the latest episode of People Behind The Science: https://amgen.ly/493gEGi

🎧 Tune in to hear him talk about his career journey, hobbies, his battle with pediatric cancer that led him to science and all the exciting work the Amgen R&D team is now doing around multispecifics and proximity-based therapeutics. 

What leadership qualities reflect our mission to serve patients? That’s what our R&D team asks each year when it’s time to nominate their leaders of the year. This tradition is an opportunity to celebrate exemplary leadership in R&D who advance an organization-wide culture of best-in-class leadership! Learn more about our collaborative culture: https://bit.ly/3GYzpOX

🔊 Tune into the latest episode of the National Association of Specialty Pharmacy (NASP) podcast featuring Amgen's Bethany Kalich, PharmD: https://amgen.ly/3uqJzVQ  

In this insightful session, Bethany discusses the vital role pharmacists and healthcare agencies play in reducing gender disparities in cardiovascular health. Amgen is actively committed to addressing cardiovascular inequities to enhance women's heart health. 

Metric
Company Name	Amgen Inc.	LégiaPark	Acerta Pharma	ATXA Therapeutics
Symbol	AMGN
MSH ID	COM:AMGEN	BE:LEGIAPARK	COM:ACERTA-PHARMA	COM:ATXATHERAPEUTICS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Life Sciences	Pharmaceutical	Pharmaceuticals
Country	US	BE	NL	IE
Stage
Employee Count	26.70K
Website	amgen.com	legiapark.be	acerta-pharma.com	atxatherapeutics.com
LinkedIn	amgen	l%C3%A9giapark
Founders

Metric
Market Cap	172.56B
Enterprise Value
Monthly Web Traffic	1.00M
Web Traffic Growth	-0.02
Valuation
Raised Capital	28.50B

Metric
Revenue	28.19B
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.74B
EBITDA	7.90B
Operating Income	7.90B
Net Income	6.72B
EPS	12.56
Diluted EPS	12.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.70
Operating Profit Margin	0.32
EBITDA Margin	0.28
Net Profit Margin	0.24
Return on Equity	1.03
Return on Assets	0.07
Return on Capital Employed	0.12

COM:AMGEN

Amgen Inc.

Last Close

289.90

22/11 21:00

Market Cap

172.56B

Beta: -

Volume Today

3.05M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	22.81
P/B Ratio	22.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.11
EV Multiple	12.57

Metric
Days Sales Outstanding	83.59
Days Payables Outstanding	69.95
Days Inventory Outstanding	411.08
Operating Cycle	513.92
Cash Conversion Cycle	445.24
Asset Turnover	0.34

Metric
Operating Cash Flow	8.47B
Free Cash Flow	7.36B
Cash Flow to Debt	0.13
Operating Cash Flow/Sales	0.30
Free Cash Flow Yield	0.06

Metric
Cash & Equivalents	10.94B
Accounts Receivable	-1.01B
Inventory	9.52B
Goodwill	18.63B
Debt to Capitalization	0.93
Debt to Assets	0.67
Current Ratio	2.86
Quick Ratio	1.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03
R&D to Revenue	0.17
SG&A to Revenue